GHRH antagonists and agonists show unexpected potential for diabetes by improving beta-cell function and insulin sensitivity | Research

The takeaway

Both GHRH agonists and antagonists demonstrate diabetes-relevant effects: agonists through beta-cell regeneration and insulin secretion, antagonists through anti-inflammatory and anti-oxidative mechanisms—offering novel peptide-based diabetes approaches.

Beta-cell regeneration potential
GHRH agonists directly promote beta-cell survival and proliferation—addressing the root cause of diabetes rather than just compensating for cell loss

What the researchers found

GHRH agonists: beta-cell regeneration, survival, insulin secretion via direct islet receptor activation. GHRH antagonists: anti-inflammatory, anti-oxidative effects relevant to diabetes complications. Both offer mechanisms distinct from existing diabetes drugs.

Why it matters

Current diabetes drugs eventually lose effectiveness. GHRH peptides offer fundamentally different mechanisms—potentially regenerating beta-cells rather than just compensating for their loss.

How the study worked

Narrative review of GHRH agonist and antagonist biology and their diabetes-relevant mechanisms.

What this study cannot tell us

Mostly preclinical evidence. Clinical translation of GHRH peptides for diabetes not yet attempted. Growth hormone effects may complicate systemic use.

How to read the evidence

Narrative review of preclinical evidence. Novel concept needing clinical validation.

When this study was published

Published in 2025.

The bigger picture

While GLP-1 drugs dominate diabetes peptide therapeutics, GHRH-based approaches address the root cause—beta-cell loss—rather than just improving insulin action. Regenerative approaches could transform diabetes from managed to cured.

Questions still open

Could GHRH agonists regenerate beta-cells sufficiently for diabetes remission?
Would growth hormone side effects limit GHRH agonist use?
Could GHRH peptides complement GLP-1 drugs?

Common questions

What is GHRH and how could it help diabetes?

Growth hormone-releasing hormone (GHRH) is best known for stimulating growth hormone release, but it also directly acts on insulin-producing beta-cells in the pancreas. GHRH agonists can promote beta-cell survival and regeneration—potentially restoring the cells lost in diabetes rather than just managing the consequences of their loss.

How is this different from GLP-1 drugs?

GLP-1 drugs primarily suppress appetite and improve existing insulin release. GHRH approaches could potentially regenerate the beta-cells themselves, addressing the fundamental problem in diabetes. Additionally, GHRH antagonists have anti-inflammatory effects relevant to preventing diabetes complications.

Read the original research

GHRH in diabetes and metabolism.

Reviews in endocrine & metabolic disorders, 26(3), 413-426

View on PubMed ↗Publisher’s paper ↗

Citation

Steenblock, Charlotte; Bornstein, Stefan R. (2025). GHRH in diabetes and metabolism.. Reviews in endocrine & metabolic disorders, 26(3), 413-426. https://doi.org/10.1007/s11154-024-09930-9